Pharmaceutical Technology Europe, Oct 1, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Oct 1, 2011
Editor's Comment
Taking It For Granted
By Rich Whitworth
As editor of Pharmaceutical Technology Europe, I often have the opportunity to visit the sites of a wide variety of companies within the industry. Though differing vastly in the technologies and staff they employ, they all share one thing in common for me: the "you learn something new every day!" factor.
Special Feature
Standing Out In The Outsourcing Crowd
By Mark Quick
The contract services industry is a crowded market and it's important for companies to differentiate themselves to stand out.
Trends and Challenges in Biologics Outsourcing
By Stephen Taylor
In a quick-fire interview, Dr Stephen Taylor, Vice President & Commercial Director at Fujifilm Diosynth Biotechnologies, looks at some of the challenges facing biologics outsourcing.
Challenges In The Changing Outsourcing Landscape
By Oriol Prat , Marga Viņes
Oriol Prat, Marketing Manager, and Marga Viñes Senior Product Manager, from Grifols give us a quick rundown of how business is changing and what challenges the company faces.
EU Market Challenges
By Michael Rooney
Although the European market is approximately 50% smaller than the US in terms of landmass, the population of Europe is approximately 50% larger and this presents a huge market opportunity.
Why Good Records Management Is Key
By Karen Redding , Eldin Rammell
The past year has seen significant consolidation of mid-size CROs, with many of them being bought or put up for sale. In particular, the top six or seven CROs seem to be signing more preferred partner deals, such as Pfizer teaming with Parexel and ICON, and Takeda?s deals with Covance and Quintiles, which is driving mid-size CROs growth through major acquisitions.
Overcoming The Distance
By Mark Berry
With the Western world recovering slowly from a recession, and tighter restrictions for medical products being applied by the FDA and other regulatory authorities, more medical device R&D is being located in Asia.
Industry Insider
Europe Edging Towards Electronic Prescribing
By Nathan Jessop
Electronic prescribing has grown strongly in the US but its future as a European-wide approach in healthcare has been uncertain; new regulatory interest could change the playing field.
Interview
Novel Excipients: A Rare Species
By Karl Kolter
Where are the new excipients, the new solubilisers and sustained release excipients?
News
News
By Stephanie Sutton
Pharmacovigilance: have your say
Agent-In-Place
Time Is Of The Essence
By Control, a senior compliance officer
Giving contamination time to build up can cause headaches for more than just your company.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here